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Abstract
Context: Monopolar transurethral resection of the prostate (M-TURP) is the current UK
surgical standard of care for benign prostatic hyperplasia, a condition estimated to affect
>2 million men in the United Kingdom. Although M-TURP efficacy in prostate resection
is established, potential perioperative complications and associated costs remain a
concern.
Objective: To present up-to-date and robust evidence in support of bipolar transurethral
resection in saline (TURis) as an alternative surgical option to M-TURP.
Evidence acquisition: A systematic review (SR) of electronic databases (up to 2015) for
randomised controlled trials (RCTs) comparing TURis with M-TURP was conducted,
followed by evidence synthesis in the form of a meta-analysis of hospital stay, cathe-
terisation time and procedure duration, transurethral resection (TUR) syndrome, blood
transfusion, clot retention, and urethral strictures. An economic analysis was subse-
quently undertaken from the UK National Health Service hospital perspective with costs
and resource use data from published sources.
Evidence synthesis: The SR identiﬁed 15 good-quality RCTs, of which 11 were used to
inform the meta-analysis. TURis was associated with improved safety versus M-TURP,
eliminating the risk of TUR syndrome and reducing the risk of blood transfusion and clot
retention (relative risks: 0.34 and 0.43, respectively; p < 0.05). TURis also reduced
hospital stay (mean difference: 0.56 d; p < 0.0001). The economic analysis indicated
potential cost savings with TURis versus M-TURP of up to £204 per patient, with
incremental equipment costs offset by savings from reduced hospital stay and fewer
complications.
Conclusions: The TURis system is associated with signiﬁcant improvements in periop-
erative safety compared with M-TURP while ensuring equivalent clinical outcomes of
prostate resection. The safety beneﬁts identiﬁed may translate into cost savings for UK
health services.
Patient summary: Our review of bipolar transurethral resection in saline, the new
prostate resection technique, indicates that it offers equal efﬁcacy while reducing
complications and length of hospital stay.soc
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Benign prostatic hyperplasia (BPH) is the most common
cause of lower urinary tract symptoms (LUTS) in men [1]
including high urinary frequency, nocturia, and urgency
(storage symptoms), and weak or intermittent urinary
stream, incomplete bladder emptying, and postmicturition
dribbling (voiding symptoms) [2,3]. Prevalence of LUTS
increases with age; approximately one-third of men aged
>65 yr experience symptoms that negatively affect daily
living [3]. Patients experience quality-of-life reductions that
increase with symptom severity; 45–54% of patients with
moderate to severe symptoms report anxiety and/or
depression [4]. Treatment of BPH and LUTS places a
considerable cost burden on health care services. In
2008–2009, estimated total UK annual drug therapy cost
for BPH was >£69 million. Secondary care costs of treating
BPH were estimated at £112 million per annum, £55 million
attributable to BPH-related surgery [5].
In men with mild/moderate LUTS, current UK and
European guidelines recommend conservative manage-
ment involving watchful waiting with or without beha-
vioural and dietary modification, or medication to control
symptoms [3,6]. Surgical intervention is offered to patients
with severe voiding symptoms presumed secondary to BPH
or if first-line treatment is unsuccessful or considered
inappropriate [3,6]. Transurethral resection of the prostate
(TURP) is the most commonly used surgical procedure
for endoscopic removal of excess prostate tissue in
the treatment of BPH [7] and is recommended for prostate
volumes of 30-80 g [6]. Other surgical interventions include
laser vaporization, enucleation, and open prostatectomy,
restricted to patients with estimated prostate sizes >80 g
[3,8].
The most common perioperative complications of TURP
are postoperative bleeding requiring transfusion (1–3% of
patients) [9,10], clot retention (2–5% of patients) [11],
urinary tract infection (4% of patients) [10], and urethral
strictures (2–10% of patients) [11]. A further potential and
possibly severe complication of TURP is systemic absorption
of irrigation fluid [12]. Monopolar TURP (M-TURP), the
system conventionally used for surgical treatment of BPH,
uses a glycine, sorbitol, or mannitol solution as a
nonconducting irrigation fluid [12]. Excessive systemic
absorption of this solution during the procedure can result
in transurethral resection (TUR) syndrome, reported to
occur in 1.4% of procedures [10]. Symptoms of TUR
syndrome include headache, bradycardia, abdominal dis-
tension, nausea and vomiting, confusion, and convulsions
[13]. Untreated, it can lead to pulmonary or cerebral
oedema or coma [13,14], or death in 0.2–0.8% of cases [15].
In England and Wales, an estimated 15 000 prostate
resection procedures are performed annually [16]. Over the
last 10 yr, use of M-TURP for surgical treatment of BPH has
been challenged by the introduction of novel procedures
including bipolar technology. Bipolar electrosurgical tech-
niques, where both active and return electrodes are
contained in the resectoscope, are currently the most
extensively investigated alternative to M-TURP [17]. ThisPlease cite this article in press as: Treharne C, et al. Economic Value
of Benign Prostatic Hyperplasia in England and Wales: Systematic 
Focus (2016), http://dx.doi.org/10.1016/j.euf.2016.03.002design means that no patient return electrode is required,
enabling the use of a physiologic saline irrigation fluid.
Because the saline is near isotonic with blood, the risk of
TUR syndrome as a result of systemic uptake is minimised
[17]. The fluid volume uptake should still be carefully
monitored, especially in patients with cardiac or pulmonary
conditions. A comparison of the efficacy and safety of these
techniques was recently performed by Cornu et al [18]. Al-
though it is acknowledged that bipolar TURP (B-TURP)
offers a more favourable perioperative safety profile than
M-TURP [6,19], there is currently no European consensus on
its use.
The transurethral resection in saline (TURis) system uses
a bipolar generator, where the energy creates a plasma
corona at the electrode tip. The case for adopting TURis as a
bipolar alternative to M-TURP was recently evaluated in the
National Institute for Health and Care Excellence (NICE)
medical technologies evaluation programme (MTEP). The
evaluation resulted in publication of NICE medical technol-
ogy guidance 23 (MTG23) in February 2015. It concluded
that clinical and economic evidence supports the adoption
of TURis for the surgical treatment of BPH [20]. The adoption
of TURis is not anticipated to be associated with a steep
learning curve given the similarity of the resection
technique to M-TURP.
To incorporate recently published evidence for TURis
versus M-TURP, we conducted an update to the original
systematic review (SR), meta-analysis, and economic
analysis presented in the manufacturer’s MTEP submission.
Preliminary results were presented at the 2015 World
Congress of Urology [21].
2. Evidence acquisition
2.1. Methods
An SR was performed to identify clinical trials to form the
basis of a meta-analysis. The results of the clinical meta-
analysis form one part of our objective. They were also used
as input for an economic analysis, the second part of our
objective.
2.2. Systematic review of the clinical evidence
The SR was performed in line with guidance by the Centre
for Reviews and Dissemination, University of York [22]. The
detailed SR methodology, as well as results and quality
assessment, is reported in the supplementary information
for MTG23 [20]. We performed an update to the original
search on April 20, 2015, limited to randomised controlled
trial (RCT) publications from 2014 onwards. The output
from this update was then combined with that from the
original SR (Table 1).
2.3. Meta-analysis of the clinical evidence
Expert opinion solicited during development of the MTEP
submission suggested that differences are most commonly
observed between TURis and M-TURP in the incidence of of the Transurethral Resection in Saline System for Treatment
Review, Meta-analysis, and Cost–Consequence Model. Eur Urol
Table 1 – Selection criteria for published and unpublished studies
Inclusion criteria
Published studies Unpublished studies
Population Adults with LUTS presumed secondary to BPH, for whom surgical intervention, mostly commonly TURP, is indicated
Individuals with prosthetic lower limbs or cardiac pacemakers
Interventions TURis
Monopolar TURP
Outcomes Hospital length of stay
Procedural blood loss and blood transfusion requirement
Time of removal of urinary catheter postoperatively
TUR syndrome
Readmittance for repeat procedures
Duration of surgical procedure
Incidence of clot retention
Quality of life
Device-related adverse events
Study design Any clinical study
Language restrictions English-language full papers
English abstracts of foreign-language papers
Search dates Medline in-process and other nonindexed citations and Ovid Medline:
1946–present
Embase: 1980–2014, week 9
EBM Reviews: NHS Economic Evaluation Database, ﬁrst quarter 2014
EBM Reviews: Cochrane Central Register of Controlled Trials, January 2014
EBM Reviews: Cochrane Database of Systematic Reviews, 2005 to January 2014
EBM Reviews: Database of Abstracts of Reviews of Effects, ﬁrst quarter 2014
EBM Reviews: Health Technology Assessment, ﬁrst quarter 2014
Econlit: 1886 to February 2014
NA
Exclusion criteria
Population NA
Indication Prostate cancer
Interventions Bipolar TURP devices other than TURis
Plasmakinetic vaporisation
Comparator interventions other than monopolar TURP (eg, laser prostatectomy)
Outcomes NA
Study design NA
Language restrictions Non–English language
Search dates NA
BPH = benign prostatic hyperplasia; EBM = evidence-based medicine; LUTS = lower urinary tract symptoms; NA = not applicable; NHS = National Health
Service; TURis = transurethral resection in saline; TURP = transurethral resection of the prostate.
E U R O P E A N U R O L O G Y F O C U S X X X ( 2 0 1 6 ) X X X – X X X 3
EUF-134; No. of Pages 10TUR syndrome, blood transfusions, clot retention, and
hospital stay. The evidence was synthesised using pairwise
meta-analysis techniques to determine any evidence-based
differences between the treatments in these outcomes, as
well as in other commonly reported outcomes including
urethral strictures, catheterisation time, and procedure
duration. According to the Cochrane Systematic Review
Handbook, a minimum of 10 studies is required to draw
meaningful conclusions from random-effects calculations
[5]. Because each meta-analysis undertaken involved
<10 studies, fixed-effects analyses were conducted. Details
of the meta-analysis methodology were previously reported
[20].
2.4. Economic evaluation
The economic analysis (a cost-consequence analysis)
compared costs and outcomes associated with TURis and
M-TURP, respectively, for surgical treatment of BPH. The
perspective of the analysis was that of the National Health
Service (NHS) and Personal Social Services in England and
Wales.Please cite this article in press as: Treharne C, et al. Economic Value
of Benign Prostatic Hyperplasia in England and Wales: Systematic R
Focus (2016), http://dx.doi.org/10.1016/j.euf.2016.03.0022.5. Patient population
The analysis considered adult men with LUTS presumed
secondary to BPH, in whom surgical intervention was
indicated.
2.6. Model structure
A decision-tree model was constructed in which men with
BPH-related LUTS underwent surgery with either TURis or
M-TURP. Patients entered the model at the point of being
indicated for surgery and were allocated probabilities of
experiencing procedure-related adverse events (TUR syn-
drome, blood transfusion, and clot retention) based on the
meta-analysis output. Procedure duration was excluded
from the analysis because no statistically significant
difference was observed between M-TURP and TURis in
the meta-analysis. The pooled reduction in catheterisation
time estimated from the meta-analysis of 0.2 d for TURis
versus M-TURP was statistically significant. However, given
that a patient’s catheter would generally be removed while
in the hospital, this reduction is not expected to result in of the Transurethral Resection in Saline System for Treatment
eview, Meta-analysis, and Cost–Consequence Model. Eur Urol
searching for clinical and cost studies:
No. of records idenﬁed through database
n = 1116
n = 919
No. of records assessed for eligibility at second pass:
n = 136
n = 24 (13 full papers, 11 abstracts)
n = 25 (14 full papers, 11 abstracts)
No. of duplicates:
n = 197
Exclusion ﬁrst pass: 
n = 783
References excluded: 
n = 112
Updated search (April 2015): n = 63
Duplicates: n = 5
Exclusion ﬁrst pass: n = 56
No. of records screened at second pass: n = 2
No. of relevant publicaons: n = 1
No. of records screened (by tle and abstract):
Relevant publicaons from original search:
Included publicaons:
Fig. 1 – Flow diagram of study selection.
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hospital stay, which was modelled. As such, catheterisation
time was not modelled explicitly. The model considered a
nondefined short time horizon covering the prostate
resection procedure and immediately afterwards—
the period during which the complications modelled are
expected to occur. Capital costs assumed equipment life
spans of 7 yr. Based on findings of the SR, no difference in
functional outcomes (eg, efficacy) was assumed between
the procedures with respect to prostate resection weight or
radicality.
2.7. Model parameters and data sources
Supplementary Table 1 lists all the variables included in the
analysis. Sourcing of inputs, rationale, and further details
are provided in Supplement 1.
2.8. Sensitivity analysis
Sensitivity analyses (based on predefined scenarios) were
conducted. The first scenario considered all-cause readmis-
sion following a TURP procedure, based on data from the
single study identified, Fagerstrom et al [23], which
indicated a threefold increase in all-cause readmission for
M-TURP versus TURis. This study reported readmissions as a
result of bleeding, infection, and ‘‘other causes.’’ Because the
base-case analysis included clot retention, the scenario
considered readmissions from infection and other causes to
avoid double counting (it is assumed that ‘‘bleeding’’
includes clot retention). A separate scenario considered a
situation in which TURis is performed as day-case surgery.
One-way deterministic sensitivity analysis was per-
formed in which all model parameters were varied either
according to published ranges or by 25%. Results are
presented as Tornado diagrams. Probabilistic sensitivity
analysis (PSA) was also conducted, in which input parameters
were varied according to specified probability distributions.
Threshold analysis was conducted to explore the relationship
between key model parameters and model results up to the
point at which the main conclusions of the model might
change, that is, in this case to determine the value at which
TURis would be cost neutral (ie, no longer cost saving) versus
M-TURP.
3. Evidence synthesis
3.1. Clinical evidence
The original electronic searches identified a total of
1116 publications. Following title and abstract review,
783 were excluded and 14 relevant RCTs remained,
following assessment of the full paper. No unpublished
studies were identified from ClinicalTrials.gov. The updated
search identified a total 63 further publications, of which
two full-text RCT publications remained after review of title
and abstract [24,25]. On review of the full text, it was found
that both of these publications reported data from the same
trial, and only the most recent publication, reporting thePlease cite this article in press as: Treharne C, et al. Economic Value
of Benign Prostatic Hyperplasia in England and Wales: Systematic 
Focus (2016), http://dx.doi.org/10.1016/j.euf.2016.03.002most up-to-date data, was included in the analysis [24].
Figure 1 shows the study selection flow diagram.
Quality assessment of the identified RCT (Supplementary
Table 2) showed that the patient population was consistent
with the target population of the analysis. Study end points
were clear and appropriately measured according to study
design and follow-up schedule.
3.2. Meta-analysis
Six studies were found to be suitable for inclusion in the
pairwise meta-analysis of the incidence of TUR syndrome
[23,26–30]. The total number of events reported in
the studies is presented in Table 2. There were no TUR
syndrome events in the TURis arm reported in any of the
studies, consistent with the use of saline. The analysis
estimated a pooled relative risk (RR) for TUR syndrome of
0.18 (95% confidence interval [CI], 0.05–0.61; p = 0.006) in
favour of TURis.
Eight RCTs reported the incidence of blood transfusion,
but only seven of these were included in the meta-analysis
[23,24,26–29,31] (Table 2). The study by Michielsen et al
was excluded from the analysis because a higher proportion
of TURis procedures was conducted by trainee surgeons
compared with M-TURP (32% vs 7%, respectively), resulting of the Transurethral Resection in Saline System for Treatment
Review, Meta-analysis, and Cost–Consequence Model. Eur Urol
Table 2 – Results of the meta-analysis of randomised controlled trials of transurethral resection in saline versus monopolar transurethral
resection of the prostate
Outcome No. of studies analysed
[references]
Patients, n Events, n RR for TURis versus M-TURP
(95% CI)
p value
TURis M-TURP TURis M-TURP
TUR syndrome 6 [19,22–26] 767 734 0 13 0.18 (0.05–0.61) 0.006
Blood transfusion 7 [19,20,22–25,27] 595 580 14 40 0.34 (0.18–0.61) 0.0003
Clot retention 6 [20,22,24,25,27,28] 594 594 11 26 0.43 (0.22–0.86) 0.0161
Urethral strictures 7 [19,20,22,24,25,27,29] 821 804 50 39 1.27 (0.85–1.9) 0.2474
Patients, n Weighted mean Mean difference for TURis
(95% CI)
p value
TURis M-TURP TURis M-TURP
Hospital stay, d 4 [20,22,23,29] 490 478 2.87 3.43 0.56 (0.77 to 0.35) <0.0001
Catheterisation time, d 4 [20,22,23,29] 469 459 1.87 2.10 0.23 (0.38 to 0.09) 0.0019
Procedure time, min 6 [20,22,25,27,29,30] 676 654 55.58 56.53 0.95 (3.35 to 1.46) 0.439
CI = conﬁdence interval; M-TURP = monopolar transurethral resection of the prostate; RR = relative risk; TUR = transurethral resection; TURis = transurethral
resection in saline.
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increased blood loss and, consequently, blood transfusions
[32]. Exclusion of this study on the basis of heterogeneity
was accepted by the External Assessment Centre for MTG23
[19]. The results of the meta-analysis showed a statistically
significant reduction in blood transfusions with use of TURis
compared with M-TURP (RR: 0.34; 95% CI, 0.18–0.61;
p = 0.0003).
Six studies were identified for meta-analysis of the
incidence of clot retention [24,26,28,29,31,32]. The pooled
RR was 0.43 in favour of TURis (95% CI, 0.22–0.86;
p = 0.0161), demonstrating that use of TURis is associated
with fewer cases of clot retention than M-TURP (Table 2).
Meta-analysis was conducted on seven studies reporting
data on urethral strictures [23,24,26,28,29,31,33]. A non-
significantly different pooled RR of 1.27 (95% CI, 0.85–1.9;
p > 0.05) was observed for TURis versus M-TURP (Table 2).
As a result, this outcome was not considered in the
economic analysis.
Further meta-analyses suggested that TURis is associat-
ed with statistically significant reductions in hospital stay
and catheterisation time (Table 2). For these outcomes,
meta-analyses were restricted to studies reporting both theTable 3 – Potential cost savings with transurethral resection in saline 
Cost category, £ Costs: e
M-TURP TURis
Capital equipment – 9.68 (29
Procedure consumables 137.75 (66.84) 161.14 (16
Hospital stay 852.60 (852.60) 687.58 (68
Complications 95.14 (95.14) 23.32 (23
Total 1085.49 (1014.58) 881.71 (90
With inclusion of readmission due to all causes in the model
Capital equipment – 9.68 (29
Procedure consumables 137.75 (66.84) 161.14 (16
Hospital stay 852.60 (£852.60) 687.58 (68
Complications 95.14 (95.14) 23.32 (23
Repeat procedures 66.70 (66.70) 25.38 (25
Total 1152.19 (1081.28) 907.09 (92
M-TURP = monopolar transurethral resection of the prostate; TURis = transurethr
* Based on 150 procedures per annum.
Please cite this article in press as: Treharne C, et al. Economic Value
of Benign Prostatic Hyperplasia in England and Wales: Systematic R
Focus (2016), http://dx.doi.org/10.1016/j.euf.2016.03.002mean duration and standard deviation. From a pooled
analysis of four studies reporting length of hospital stay
[24,26,27,33], the mean difference for TURis versus M-TURP
was 0.56 d (95% CI, 0.77 to 0.35; p < 0.0001). Analysis
of four studies presenting data on catheterisation time
[24,26,27,33] resulted in a statistically significant mean
difference for TURis versus M-TURP of 0.23 d (95% CI,
0.38 to 0.09; p = 0.0019); however, this difference is not
clinically meaningful because such a minimal reduction in
catheterisation time is unlikely to make a considerable
difference to patients. Six studies reported procedure
duration [24,26,29,31,33,34] and, although not significant,
the resulting pooled mean difference for TURis versus
M-TURP was 0.95 min (95% CI, 3.35 to 1.46; p > 0.05).
3.3. Economic analysis
Only statistically significant differences in clinical outcomes
in the meta-analysis, which directly affect costs, were
considered in the base-case analysis: TUR syndrome, blood
transfusions, clot retention, and length of hospital stay.
Table 3 shows the results of the base-case analysis. Costs of
adopting TURis differed according to whether or not hospitalsversus monopolar transurethral resection of the prostate*
xisting (nonexisting) Olympus centre
 Difference Relative difference, %
.13) 9.68 (29.13) –
1.14) 23.39 (94.30) 17 (141)
7.58) 165.02 (165.02) 19 (19)
.32) 71.82 (71.82) 75 (75)
1.16) 203.78 (113.42) 19 (11)
.13) 9.68 (29.13) –
1.14) 23.39 (94.30) 17 (141)
7.58) 165.02 (165.02) 19 (19)
.32) 71.82 (71.82) 75 (75)
.38) 41.32 (41.32) 62 (62)
6.53) 245.10 (154.75) 21 (13)
al resection in saline.
 of the Transurethral Resection in Saline System for Treatment
eview, Meta-analysis, and Cost–Consequence Model. Eur Urol
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procedures per annum, capital costs of TURis (Supplementa-
ry Table 1) for hospitals with existing Olympus systems and
for those without Olympus systems were £9.68 and £29.13
per patient per year, respectively. The total cost per patient
(including capital equipment, consumables, hospital stay,
and complications) of using TURis for hospitals with Olympus
systems in place was £881.71 versus £1085.49 for M-TURP, a
cost saving of £203.78 per patient. In hospitals without
Olympus systems, the total per patient cost of using TURis
was £901.16 compared with £1014.58 for M-TURP, a cost
saving of £113.42 per patient.
Higher equipment costs for TURis versus M-TURP were
offset by savings from reductions in hospital stay and
complications. Assuming a reduction in hospital stay of
0.56 d from the meta-analysis, the base-case analysis found
that TURis was associated with a £165.02 reduction in the
cost of hospital stay per patient versus M-TURP. TURis was
also associated with a £71.82 per patient reduction in
complication costs compared with M-TURP.
A further potential benefit of the TURis system is the
option of conducting surgery on a day-case basis. Some UK–£30
TURis reduction in hospital stay, d (0.35–0.77; base case 0.56) a
b
Inpatient day cost (£197–£344; base case £294) 
TURP consumables cost per procedure (£50–£84; base case £67) 
TURis loop unit cost (£95–£158; base case £127) 
TURis clot retention relative risk (0.21–0.85; base case 0.43) 
TURP TUR syndrome rate (1.33–2.21%; base case 1.77%) 
Cost per case of TUR syndrome (£1532–£2553; base case £2042) 
Cost of clot retention (£365–£1064; base case £829) 
TURis roller unit cost (£118–£196; base case £157) 
Roller TURis proportion use (16.5–27.5%; base case 22.0%) 
–£180
TURis reduction in hospital stay, d (0.35–0.77; base case 0.56) 
Inpatient day cost (£197–£344; base case £294) 
TURis loop unit cost (£95–£158; base case £127) 
TURP consumables cost per procedure (£50–£84; base case £67) 
TURis clot retention relative risk (0.21–0.85; base case 0.43) 
Cohort size - direct input (100–200; base case 150) 
TURP TUR syndrome rate (1.33–2.21%; base case 1.77%) 
Cost per case of TUR syndrome (£1532–£2553; base case £2042) 
Cost of clot retention (£365–£1064; base case £829) 
TURis roller unit cost (£118 –£196; base case £157) 
Fig. 2 – Results of the one-way sensitivity analysis. (A) Existing Olympus mono
TUR = transurethral resection; TURis = transurethral resection in saline; TURP =
Please cite this article in press as: Treharne C, et al. Economic Value
of Benign Prostatic Hyperplasia in England and Wales: Systematic 
Focus (2016), http://dx.doi.org/10.1016/j.euf.2016.03.002centres are already adopting this practice [35,36], and the
potential for further cost savings in hospital stay costs via
this practice was acknowledged by NICE in MTG23
[20]. Although in clinical practice various factors influence
the implementation of day-case surgery, testing a scenario
reflecting this situation, in which patients undergoing TURis
incurred no inpatient day costs, cost savings were £891.36
and £801.00 per patient, for Olympus and non-Olympus
centres, respectively.
Considering readmissions in a further scenario, TURis
was associated with annual cost savings versus M-TURP of
£245.10 and £154.75 per patient, for Olympus and non-
Olympus centres, respectively (Table 3). Readmission for
BPH is not widely reported, thus data relating to this
outcome are limited; the scenario analysis was based on a
single study [23].
Sensitivity analysis also demonstrated that TURis
remained cost saving versus M-TURP when each tested
model parameter was varied according to its defined range.
Key drivers of cost savings were reduction in hospital stay
and inpatient day costs (Fig. 2). Results of PSA demonstrated
that the cost-consequence analysis was robust across both–£100 –£150 –£200 –£250 0 
Cost saving for TURis 
Low value 
High value 
–£40 –£60 –£80 –£100 –£120 –£140 –£160  
Cost saving for TURis 
Low value 
High value 
polar centre; (B) non-Olympus monopolar centre.
 transurethral resection of the prostate.
 of the Transurethral Resection in Saline System for Treatment
Review, Meta-analysis, and Cost–Consequence Model. Eur Urol
Table 4 – Results of the threshold analysis
Variable Base case
(CI: lower–upper)
Cost neutral:
existing Olympus
centre
Cost neutral:
non-Olympus
centre
Cohort size 150 (100–200) 7 patients 31 patients
Probability of TUR syndrome with TURP, % 1.77 (1.33–2.21) NA NA
Probability of blood transfusion with TURP, % 6.90 (5.17–8.62) NA NA
Probability of clot retention with TURP, % 4.38 (3.28–5.47) NA NA
Relative risk of blood transfusion for
TURis versus TURP, %
0.34 (0.18–0.61) 9.32 5.34
Relative risk of clot retention for TURis versus TURP 0.43 (0.21–0.85) 6.05 3.56
Total capital cost for TURis at non-Olympus centre, £ 26 715 (20 036–33 394) – 130 744
Total capital cost for TURis at existing Olympus
monopolar centre, £
8880 (6660–11 100) 195 781 –
Life span for TURis capital equipment, yr 7 (5–10) 0.28 1.30
Discount rate for costs, % 3.5 (0–6) NA 79
Overall consumables cost for TURP per procedure, £ Existing monopolar centre:
138 (103–172)
Non-Olympus centre:
67 (50–84)
NA NA
Use of TURis rollers as a proportion of all TURis
electrode use, %
22 (17–28) NA 94
Mean length of inpatient stay after prostate resection
procedure with TURP, d
2.9 (2.2–3.6) NA NA
Reduction in length of stay associated with TURis, d 0.56 (0.35–0.77) NA 0.18 d
Cost per inpatient day in general ward, £ 294 (197–344) NA 91.93
Incremental cost for a patient experiencing TUR syndrome, £ 2042 (1532–2553) NA NA
Incremental cost for a patient requiring a blood transfusion, £ 329 (247–411) NA NA
CI = conﬁdence interval; NA = not applicable; TUR = transurethral resection; TURis = transurethral resection in saline; TURP, transurethral resection of the
prostate.
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associated with a mean saving of £200.77 per patient (95%
CI, £115.54 to £298.67) and remained cost saving in all
1000 simulations. For Olympus centres, the mean saving
was £112.93 per patient (95% CI, £32.94 to £211.22), and
TURis remained cost saving in 99.8% of simulations.
Results of the threshold analysis on model parameters
(Table 4) confirmed the robustness of the base-case results.
Existing Olympus centres would need to perform as few as
seven procedures annually for TURis to become cost saving
versus M-TURP. For non-Olympus centres, the number
is 31. Keeping all other model parameters constant, TURis
would need to be associated with significantly increased
risks of blood transfusion and clot retention compared with
M-TURP to cease being cost saving overall. Based on the
findings of the meta-analysis, which showed statistically
significant reductions in these events for TURis versus TURP,
it is not considered plausible that RRs as high as those
reported in Table 4 would be observed for TURis versus
M-TURP.
Significant increases in the annual cost of capital
equipment for TURis would be required for TURis to cease
being cost saving versus M-TURP. This could only happen as
a result of short equipment life span in practice because
prices are generally stable over a period such as the
modelled time horizon. The shortened life spans that would
be required for TURis to cease being cost saving versus
M-TURP (0.28 yr for existing Olympus centres and 1.30 yr
for non-Olympus centres) demonstrate the robustness of
the conclusions of the analysis to changes in TURis capital
costs. TURis would cease being cost saving if the reductionPlease cite this article in press as: Treharne C, et al. Economic Value
of Benign Prostatic Hyperplasia in England and Wales: Systematic R
Focus (2016), http://dx.doi.org/10.1016/j.euf.2016.03.002in hospital stay for TURis versus M-TURP was removed (only
for non-Olympus centres).
3.4. Discussion
This study presents current and compelling clinical and
economic evidence supporting adoption of the TURis system
as an alternative to M-TURP, which is the current UK surgical
standard of care for the treatment of BPH. The analysis was
based on an SR of RCT evidence and synthesis of those data for
both systems, with a subsequent economic analysis con-
ducted from the perspective of the NHS in England and
Wales. The data synthesis (by meta-analysis) showed that
TURis was associated with significant improvements in
perioperative safety and in duration of hospital stay
compared with M-TURP. The results of the base-case
economic analysis found that the adoption of TURis could
result in cost savings versus M-TURP of £204 and £113 per
patient for existing and non-Olympus TURP centres, respec-
tively. Sensitivity analysis demonstrated that reduction in
hospital stay was a key driver of results. Inclusion of
readmissions resulted in cost savings with TURis versus
M-TURP of £245 and £155 per patient for Olympus and non-
Olympus centres, respectively. Although this analysis was
based on a single RCT (of good quality), NICE considered it
sufficiently robust [20].
Although efficacy in prostate resection surgery for
treatment of voiding symptoms presumed secondary to
BPH is well established, possible perioperative complica-
tions and associated costs remain a concern. Current
European guidelines state that B-TURP offers similar of the Transurethral Resection in Saline System for Treatment
eview, Meta-analysis, and Cost–Consequence Model. Eur Urol
E U R O P E A N U R O L O G Y F O C U S X X X ( 2 0 1 6 ) X X X – X X X8
EUF-134; No. of Pages 10efficacy to M-TURP but with reduced perioperative
morbidity. The guidelines recommend that the choice of
B-TURP should be based on surgeon experience, availability
of equipment, and patient preference [6]. Although there
is currently no European consensus on the use of a specific
B-TURP system, in England and Wales the recently
published NICE MTG23 guidance concludes that the
available evidence supports the adoption of TURis for
surgical treatment of BPH and that the TURis system is
clinically equivalent to M-TURP, but with the advantage of
reducing the risk of perioperative complications [20]. It
further states that TURis has the potential to be cost saving
compared with M-TURP [20].
The SR presented here demonstrates that the TURis
system is supported by strong clinical data in the form of
15 good quality RCTs. To our knowledge, this is the first
study to evaluate the wealth of RCT evidence in support of
TURis for conducting meta-analysis to support an economic
evaluation.
The findings from the economic analysis may have
important implications for decision makers. The results
suggest that NHS hospitals in England and Wales adopting
TURis specifically as an alternative to M-TURP can expect
both cost savings and improved clinical outcomes. Based on
the results of the meta-analyses, treating 56 people with
TURis instead of M-TURP could prevent one case of TUR
syndrome. The numbers needed to treat to avoid one blood
transfusion and one case of clot retention are 22 and 40,
respectively. Because Hospital Episode Statistics data
indicate that approximately 14 500 TURP procedures were
performed out in England in 2012–2013, approximately
260 cases of TUR syndrome might be avoided if TURis was to
replace M-TURP, along with 660 blood transfusions and
360 cases of clot retention. Given the complication costs
outlined in Supplementary Table 1, avoiding these compli-
cations alone might result in an annual cost savings of
>£1 million in England. When reductions in hospital stay
are considered, the annual cost savings exceed £3.4 million.
Beyond potential cost savings, this represents efficiency
improvements for hospitals, enhancing patient manage-
ment and throughput.
Introduction of medical devices into clinical practice is
often limited by availability of high-quality clinical evidence,
an essential component of robust economic evaluation of
any medical intervention. Large-scale RCTs are convention-
ally used as the gold standard for demonstrating clinical
efficacy of drug therapies; however, medical devices face a
range of challenges in RCT design that often affect quality. For
example, randomisation may not be possible due to ethical
constraints, and blinding (especially double blinding) may
not be feasible, thus increasing the risk of bias [37,38]. The
cohort size and timescale of follow-up and assessments may
also be limited [38]. Consequently, the clinical evidence base
for a medical device can often be weak. In contrast, this study
benefits from high-quality RCT evidence, acknowledged in
the NICE MTG23 guidance, comprising 15 studies that show
the clinical evidence for TURis supports the adoption of the
technology. Patients included in the studies have undergone
standard M-TURP or TURis procedures and no deviations inPlease cite this article in press as: Treharne C, et al. Economic Value
of Benign Prostatic Hyperplasia in England and Wales: Systematic 
Focus (2016), http://dx.doi.org/10.1016/j.euf.2016.03.002procedure protocol were observed, providing an evidence
base with low heterogeneity.
A further strength of the economic analysis is that we
only included those clinical outcomes for which meta-
analysis showed statistically significant differences be-
tween the two treatments. Assumptions regarding resource
use for complications were based on NICE clinical guideline
97 [39] and had been validated by two clinical experts for
the MTEP assessment.
The analysis is not without limitations. For meta-
analysis, a random-effects model is generally considered
more robust because it takes heterogeneity into account.
The random-effects model is only recommended, however,
if 10 studies are available for an end point, which was not
the case here. We therefore performed a fixed-effects meta-
analysis. Second, complications would vary in severity; the
costs considered in the analysis are intended to reflect the
typical cost of treating each event. Because the model is
based on UK cost data, the results are not generalizable to
other countries.
4. Conclusions
The findings of the current study demonstrate that the
TURis system specifically is supported by high-quality
evidence. TURis demonstrates equivalent efficacy versus M-
TURP, the current standard of care and is associated with
statistically significant improvements in perioperative
safety and duration of hospital stay. Improvements in
safety with TURis could reduce the incidence of readmission
following surgery. Finally, the clinical benefits of TURis have
the potential to translate into cost savings for the NHS
because TURis is not associated with a steep learning curve
for surgeons.
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